Evidence map›Paper›PMID 40695798›Full record

ArticleNature communications2025

Intestinal tuft cell subtypes represent successive stages of maturation driven by crypt-villus signaling gradients.

Julian R Buissant des Amorie, Max A Betjes, Jochem H Bernink, Joris H Hageman, Veerle E Geurts, Harry Begthel, Dimitrios Laskaris, Maria C Heinz, Ingrid Jordens, Tiba Vinck and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Julian R Buissant des AmorieCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Max A BetjesAMOLF, Amsterdam, The Netherlands.
Jochem H BerninkHubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-9332-9224
Joris H HagemanCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-1386-054X
Veerle E GeurtsOncode Institute, Utrecht, The Netherlands.
Harry BegthelOncode Institute, Utrecht, The Netherlands.
Dimitrios LaskarisOncode Institute, Utrecht, The Netherlands.
Maria C HeinzCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-2866-9155
Ingrid JordensCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-7865-2816
Tiba VinckCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Ronja M HoutekamerCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Ingrid Verlaan-KlinkCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Sascha R BrunnerCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Jacco van RheenenOncode Institute, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-8175-1647
Martijn GloerichCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-0034-4642
Hans CleversOncode Institute, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-3077-5582
Sander J TansAMOLF, Amsterdam, The Netherlands.
Jeroen S van ZonAMOLF, Amsterdam, The Netherlands.
Hugo J G SnippertCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. h.j.g.snippert-2@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0002-4189-5213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal tuft cells are epithelial sentinels that trigger host defense upon detection of parasite-derived compounds. While they represent potent targets for immunomodulatory therapies in inflammation-driven intestinal diseases, their functioning and differentiation are poorly understood. Here, we reveal common intermediary transcriptomes among the previously described tuft-1 and tuft-2 subtypes in mouse and human. Tuft cell subtype-specific reporter knock-ins in organoids show that the two subtypes reflect successive post-mitotic maturation stages within the tuft cell lineage. In vitro stimulation with interleukin-4 and 13 is sufficient to fuel the generation of new Nrep+ tuft-1 cells, arising from tuft precursors (tuft-p). Subsequently, changes in crypt-villus signaling gradients, such as BMP, and cholinergic signaling, are required to advance maturation towards Chat+ tuft-2 phenotypes. Functionally, we find chemosensory capacity to increase during maturation. Our tuft subtype-specific reporters and optimized differentiation strategy in organoids provide a platform to study immune-related tuft cell subtypes and their unique chemosensory properties.

Indexed as

Epithelial CellsIntestinal MucosaSignal TransductionAnimalsCell DifferentiationCell LineageHumansInterleukin-13Interleukin-4MiceMice, Inbred C57BLOrganoidsTranscriptomeTuft CellsInterleukin-13Interleukin-4

Identifiers

PMID40695798
PMCPMC12284190

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.